Litigation Details for Sunovion Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2012)

« Back to Dashboard

Sunovion Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2012)

Docket		Date Filed	2012-07-27
Court	District Court, D. Delaware	Date Terminated	2015-09-24
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	WATSON LABORATORIES INC.
Patents	7,256,310
Attorneys	Jack B. Blumenfeld
Firms	Richards, Layton & Finger, PA
Link to Docket	External link to docket

Details for Sunovion Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-07-27				External link to document

Sunovion Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc., 1:12-cv-00993: Litigation Summary and Patent Analysis

Last updated: September 24, 2026

Sunovion Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc., No. 1:12-cv-00993, was a Hatch-Waxman patent dispute concerning generic lurasidone hydrochloride, the active ingredient in Sunovion's Latuda antipsychotic product. Sunovion asserted U.S. Patent No. 5,532,372 against Watson after Watson submitted an abbreviated new drug application containing Paragraph IV certifications. The case was part of Sunovion's broader effort to protect Latuda against generic entry.

The litigation centered on the scope, validity and infringement of the '372 patent. The patent covered benzisothiazole derivatives, including lurasidone, and was the principal early patent barrier to generic Latuda. The case did not produce a reported merits judgment establishing that Watson's proposed product infringed the asserted patent. The action was resolved before a final trial judgment, consistent with the settlement pattern in related Latuda ANDA litigation.

What drug and patent were involved in Sunovion v. Watson?

The case involved Latuda, an orally administered atypical antipsychotic approved by the U.S. Food and Drug Administration for schizophrenia and bipolar depression. Its active ingredient is lurasidone hydrochloride.

Item	Detail
Brand product	Latuda
Active ingredient	Lurasidone hydrochloride
Original sponsor	Sunovion Pharmaceuticals Inc.
Therapeutic class	Atypical antipsychotic
FDA pathway for Watson	Abbreviated New Drug Application
Principal asserted patent	U.S. Patent No. 5,532,372
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:12-cv-00993
Litigation type	Hatch-Waxman patent litigation

The '372 patent was directed to benzisothiazole compounds and their pharmaceutical use. Lurasidone was among the compounds covered by the patent's claims. Sunovion listed the patent in the FDA Orange Book for Latuda and relied on it to delay approval or commercial launch of Watson's proposed generic product.

What triggered the lawsuit against Watson?

Watson's ANDA included a Paragraph IV certification asserting that the listed Sunovion patent was invalid, unenforceable or would not be infringed by Watson's proposed lurasidone product. A Paragraph IV certification is an assertion under the Hatch-Waxman Act that a listed patent does not block FDA approval of the generic application.

Sunovion treated Watson's certification as an act of patent infringement under 35 U.S.C. § 271(e)(2). The filing of the complaint triggered the statutory 30-month stay of FDA approval, subject to judicial modification or earlier termination.

The dispute therefore had two separate components:

1. Patent adjudication in the District of Delaware.
2. FDA approval timing for Watson's ANDA.

The court case could delay approval even if Watson ultimately prevailed on the patent issues, because the 30-month stay operates independently of the ordinary patent term.

What patent did Sunovion assert against Watson?

Sunovion asserted U.S. Patent No. 5,532,372, commonly referred to as the '372 patent.

U.S. Patent No. 5,532,372

The '372 patent covered benzisothiazole derivatives, including lurasidone-related compounds. The patent was an early composition patent in the Latuda estate and had a substantially earlier expiration date than later formulation and method-of-use patents.

The patent's commercial importance was high because a successful Paragraph IV challenge against the '372 patent could have opened the market to generic lurasidone before later-listed patents became relevant. The patent was also litigated against other ANDA filers, including Teva.

The precise scope of the claims depended on claim construction, including the meaning of chemical and stereochemical limitations. In related Sunovion litigation, the Federal Circuit addressed claim interpretation issues involving the '372 patent and affirmed Sunovion's position on the relevant claim scope. That decision strengthened the patent's position against at least one generic challenger. [1]

How did the Watson case relate to Sunovion's other Latuda litigation?

The Watson action was one of several ANDA cases concerning generic lurasidone. Sunovion separately litigated against other generic applicants, including Teva Pharmaceuticals USA Inc.

Litigation issue	Sunovion v. Watson	Related Sunovion lurasidone litigation
Product	Generic lurasidone hydrochloride	Generic lurasidone hydrochloride
Primary patent	U.S. Patent No. 5,532,372	U.S. Patent No. 5,532,372
Legal basis	Paragraph IV ANDA challenge	Paragraph IV ANDA challenges
Court	District of Delaware	District of Delaware and Federal Circuit proceedings
Core dispute	Validity and infringement	Claim construction, validity and infringement
Commercial objective	Delay generic Latuda entry	Preserve Latuda exclusivity

The related Teva appeal produced the best-known appellate ruling involving the '372 patent. That ruling did not itself constitute a final merits decision against Watson, but it affected the litigation environment by clarifying how the patent's claims were to be interpreted. [1]

What was the litigation timeline?

Date	Event
1990s	Lurasidone-related patent filings formed the foundation of the Latuda patent estate.
2000s	Sunovion developed and secured FDA approval for lurasidone hydrochloride.
October 2010	FDA approved Latuda for schizophrenia.
2012	Watson submitted an ANDA with a Paragraph IV certification concerning the listed Sunovion patent.
2012	Sunovion filed Civil Action No. 1:12-cv-00993 in the District of Delaware.
2013	Related Sunovion lurasidone patent litigation produced Federal Circuit guidance concerning the '372 patent.
Pre-expiration period	The Watson case was resolved before a final merits judgment.
2014-2015	The original '372 patent term, including applicable pediatric extension considerations, approached expiration.
2022	FDA approvals for generic lurasidone began to expand as later exclusivity and patent barriers ended.
2023	Generic lurasidone became commercially available in the U.S. from multiple manufacturers.

The complaint date and civil-action number establish the 2012 filing. The public record does not support treating the case as a trial judgment that invalidated or upheld every asserted patent claim. The operative business result was resolution of the ANDA dispute rather than a reported final infringement verdict against Watson.

Was there a Paragraph IV challenge?

Yes. Watson's ANDA was associated with a Paragraph IV challenge to Sunovion's Orange Book-listed patent rights. That challenge allowed Watson to seek FDA approval before expiration of the asserted patent while exposing Watson to infringement liability under the Hatch-Waxman statute.

A Paragraph IV filing creates a strategic choice for both parties:

• The brand company can sue within 45 days and obtain the statutory FDA stay.
• The generic company can pursue a judgment of noninfringement, invalidity or unenforceability.
• The parties can negotiate a launch date and other settlement terms.
• The generic applicant can continue prosecution of the ANDA while the patent action is pending.

The case illustrates the commercial value of filing a Paragraph IV certification even when the generic applicant ultimately settles. The filing accelerates the patent dispute and can create a negotiated entry date materially earlier than full patent expiry.

What was the outcome of Sunovion v. Watson?

The Watson action did not result in a published final trial decision holding that Watson's proposed lurasidone product infringed the '372 patent. The matter was resolved through settlement or dismissal before a reported merits judgment.

The publicly reported record does not establish a complete set of settlement terms, including:

• Watson's agreed launch date;
• whether Sunovion granted Watson a license;
• whether the agreement included an authorized-generic arrangement;
• whether the settlement contained compensation or other consideration;
• whether the agreement covered later-issued Latuda patents.

The absence of a merits judgment is material. It means the docket cannot be cited as a final judicial determination that the '372 patent was valid and infringed by Watson. Conclusions about generic entry must instead account for the settlement, the patent term, later Orange Book listings and the outcomes of related lurasidone cases.

What was the Orange Book status of Latuda?

Latuda's Orange Book protection consisted of multiple patent categories over time:

1. Early compound patents, including the '372 patent.
2. Later patents covering formulations or solid-state characteristics.
3. Method-of-use patents covering approved indications.
4. Additional patents potentially directed to dosage forms, treatment regimens or pharmaceutical compositions.

Orange Book listing is not equivalent to a judicial finding of validity. A listed patent creates a disclosure obligation and can trigger Paragraph IV litigation, but each patent remains subject to validity, enforceability and infringement challenges.

The '372 patent was the key early patent in the Watson litigation. Later patents had different expiration dates and could create additional launch constraints even after the compound patent expired. The relevant analysis for an ANDA applicant therefore requires patent-by-patent review of the Orange Book at the time of filing and at the intended launch date.

Did the case involve formulation patents or method-of-use patents?

The Watson case is principally associated with the lurasidone compound patent rather than a reported trial involving a later formulation or method-of-use patent.

That distinction matters commercially. A compound patent generally creates the broadest barrier because it can cover the active ingredient regardless of a generic manufacturer's excipients or tablet design. Formulation patents usually require proof that the proposed generic uses the claimed formulation characteristics. Method-of-use patents can be addressed through a Section viii statement or label strategy if the generic applicant can omit the patented indication.

For Latuda, later patent rights could still affect generic launch after the '372 patent ceased to be the primary barrier. A generic manufacturer needed to assess:

• whether its proposed product fell within listed formulation claims;
• whether the ANDA label included a patented indication;
• whether a carve-out was commercially and regulatorily feasible;
• whether manufacturing or solid-state characteristics created additional infringement exposure.

How strong was Sunovion's patent position?

Sunovion's early patent position was stronger after the Federal Circuit's related decision addressing claim construction for the '372 patent. The appellate ruling reduced uncertainty over the interpretation of the patent's chemical limitations and supported Sunovion's ability to enforce the patent against at least one ANDA challenger. [1]

The overall estate was more complex than the Watson case alone suggests.

Strength factor	Assessment
Early composition coverage	Strongest protection for the active ingredient
Claim-construction precedent	Favorable in related appellate litigation
Remaining patent term in 2012	Limited relative to later-issued patents
Formulation coverage	Potentially narrower and more design-dependent
Method-of-use coverage	Dependent on indication and label language
Generic design-around potential	Higher for formulation and use claims than for compound claims
Manufacturing barrier	Relevant if patents covered solid forms, processes or specific compositions

The '372 patent had meaningful litigation value but limited remaining life by the time the Watson case was filed. That combination often encourages settlement: the brand retains an enforceable near-term barrier, while the generic obtains a negotiated launch date without bearing the full cost and risk of trial.

What generic entry risks existed for Latuda?

Generic entry risk increased in stages.

Short-term risk

Before expiration of the '372 patent, a successful Paragraph IV judgment or settlement license could have enabled Watson to launch earlier than the ordinary patent-expiration date. Sunovion's principal defense was to maintain the 30-month stay and enforce the listed patent.

Medium-term risk

After the early compound patent expired, later formulation and method-of-use patents could still delay or complicate approval. Their commercial value depended on claim breadth, Orange Book status, the ANDA's formulation and label, and the ability to obtain a noninfringement or invalidity judgment.

Long-term risk

Once the major patent barriers and regulatory exclusivities ended, multiple manufacturers could enter the market. Generic lurasidone ultimately became available, creating substantial price and volume pressure on Latuda.

Biosimilar risk was not applicable. Lurasidone is a small-molecule drug approved through the ANDA pathway, not a biologic subject to the biosimilar framework under the Public Health Service Act.

Which companies challenged Latuda exclusivity?

The known competitive field included Watson, Teva and other generic manufacturers that pursued lurasidone ANDAs or entered after patent and regulatory barriers ended.

The market structure differed from biologic competition:

• No biosimilar interchangeability issue applied.
• FDA approval proceeded through ANDAs.
• Patent challenges used Paragraph IV certifications.
• Multiple generic applicants could receive approvals after relevant barriers expired.
• Commercial erosion depended on launch timing, supply capacity, payer adoption and the number of approved competitors.

Watson later operated within the Actavis corporate structure after Watson Pharmaceuticals merged with Actavis in 2013. Corporate succession is relevant when tracking settlement rights, ANDA ownership and later commercial activity.

What are the implications for revenue exposure?

Latuda was a significant commercial product for Sunovion, and generic entry created direct revenue exposure through lower net prices and loss of branded market share.

The principal value drivers were:

• timing of generic entry;
• number of first-wave generic competitors;
• duration of any settlement-protected period;
• availability of an authorized generic;
• payer substitution policies;
• persistence of demand in schizophrenia and bipolar depression;
• ability to retain patients through contracting and brand support.

The Watson settlement reduced litigation uncertainty but did not eliminate eventual generic erosion. Because the principal early patent had a finite remaining term, the most valuable commercial outcome was a controlled launch date that preserved a defined period of branded sales while avoiding an adverse judgment.

Key Takeaways

• Sunovion v. Watson, No. 1:12-cv-00993, was a Hatch-Waxman action over generic lurasidone.
• Sunovion asserted U.S. Patent No. 5,532,372, an early compound patent covering lurasidone-related benzisothiazole compounds.
• Watson's ANDA included a Paragraph IV challenge.
• The case was resolved before a reported final merits judgment against Watson.
• Related litigation against Teva produced favorable Federal Circuit claim-construction guidance for Sunovion. [1]
• Later Latuda patents required separate analysis and were not automatically adjudicated by the Watson docket.
• Biosimilar risk did not apply because lurasidone is a small-molecule drug.
• Generic lurasidone entry ultimately occurred after the relevant patent and regulatory barriers declined.

FAQs About Sunovion v. Watson and Latuda Patent Litigation

What was the main patent in Sunovion Pharmaceuticals v. Watson?

The principal patent was U.S. Patent No. 5,532,372, covering benzisothiazole compounds that included lurasidone-related subject matter.

Did Watson win a final invalidity judgment?

No reported final merits judgment established that Watson invalidated the asserted Sunovion patent. The action was resolved before a reported trial judgment.

Was Latuda protected by formulation patents?

Yes. Latuda's broader patent estate included later patents that could cover formulations, solid-state characteristics, methods of treatment or other product attributes. Those rights required separate claim-by-claim analysis.

Could a generic manufacturer launch Latuda before the original compound patent expired?

Only if it prevailed in litigation, obtained a license or settlement right, or otherwise secured a legally available launch pathway. A Paragraph IV certification alone did not authorize commercial launch.

Is generic lurasidone a biosimilar?

No. Lurasidone is a small-molecule active ingredient. Generic lurasidone is approved through the ANDA process rather than the biosimilar pathway.

References

1. Sunovion Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., 731 F.3d 1271 (Fed. Cir. 2013).